CNBC's "Fast Money" Episode Summary

Title: Stock Jump On Inflation Data & Fed Comments… And The 2024 Charts Of The Year
Host: Melissa Lee
Release Date: December 20, 2024

1. Introduction and Market Overview

Hosted by Melissa Lee, "Fast Money" delves into the day's pivotal financial events, focusing on the stock market's reaction to recent Federal Reserve comments and inflation data. The episode highlights significant movements in key stocks, government funding debates, and insights into 2024's chart-topping performances.

2. Federal Reserve Comments and Market Rebound

Timestamp: [00:59 - 05:30]

• Federal Reserve Insights:

  • Austan Goolsbee, Chicago Fed President, expressed optimism about the recent inflation data, signaling potential room for rate cuts in the coming year. "The funds rate is still substantially higher than the neutral rate. So there's room for the Fed to cut," Goolsbee stated ([02:12]).
  • John Williams, New York Fed President, echoed sentiments of significant inflation reduction but acknowledged the 2% target remains unmet. "We're still not to our 2% goal. We're going to make sure we get there," he noted ([02:56]).

• Market Reaction:

  • Following Goolsbee's comments, the Dow surged nearly 500 points, with the S&P 500 and Nasdaq each climbing over 1%. Despite this rebound, all major indices were still trailing for the week.
  • Steve Liesman observed, "Powell agrees with Goolsbee and Williams. The market overreacted to the commentary," emphasizing that the Fed's stance remains unchanged despite market volatility ([05:30]).

• Analyst Insights:

  • Tim Seymour anticipates further rate reductions over the next 12-18 months, assuming economic conditions remain favorable ([02:28]).
  • Carrie Feiderman noted that while inflation trends are improving, the consensus remains cautious about immediate rate cuts, emphasizing, "The trend is toward inflation and not a lot of cuts," ([04:19]).

3. Impact on Pharmaceutical Stocks: Novo Nordisk vs. Eli Lilly

Timestamp: [17:30 - 22:11]

• Novo Nordisk's Setback:

  • Evan David Siegerman, BMO Senior Research Analyst, discussed Novo Nordisk's significant drop of nearly 18% following disappointing results from its next-generation obesity drug. The drug showed an average weight loss of 22.7%, below expectations of 25%.
  • Notably, side effects led to only 57% of patients proceeding to the highest dose, raising concerns about the drug's viability. "It really challenges Cargill Cema. They feel like they're losing in the race," Siegerman remarked ([18:25]).
  • Siegerman further highlighted that Novo Nordisk is lagging in the oral obesity market, especially against Eli Lilly's smaller molecule pill, which offers easier manufacturing and superior efficacy ([19:42]).

• Eli Lilly's Advantage:

  • Eli Lilly's Zepbound received FDA approval for treating obstructive sleep apnea, positioning it as a leader in the space. Siegerman praised Zepbound's efficacy, stating, "It's highly efficacious and is the leading product in the market," ([18:08]).
  • Steve Liesman echoed Siegerman's optimism, noting, "Eli Lilly is now in the pole position," emphasizing the company's strong performance and market position ([21:00]).

• Future Prospects:

  • Despite current setbacks, Siegerman remains bullish on Eli Lilly, anticipating positive earnings and a robust 2025 outlook. He also speculated potential acquisitions or partnerships for Novo Nordisk to regain its competitive edge ([19:56]).

4. Government Shutdown and Debt Ceiling Negotiations

Timestamp: [13:50 - 44:08]

• Current Status:

  • Lawmakers are debating a stopgap funding bill to prevent a government shutdown, aiming to keep the government funded until March 14. The bill requires strong Democratic support to pass ([13:50]).
  • Emily Wilkins reported that the bill is likely to receive the necessary bipartisan backing, reducing fears of an imminent shutdown. "It seems like the worst-case scenario is a short weekend shutdown," she stated ([44:08]).

• Market Implications:

  • Concerns linger about potential credit rating downgrades if government dysfunction persists. Tim Seymour discussed the possible impacts on yields, noting, "US politics matter and fiscal dynamics are adding pressure," ([15:33]).
  • Carrie Feiderman compared the US debt rating to corporate counterparts, highlighting that even companies like Apple or Exxon would face challenges if rated similarly, but emphasized the US remains the most creditworthy sovereign ([17:20]).

• Resolution Outlook:

  • With Democrats increasingly supportive of keeping the government open, the likelihood of passing the funding bill strengthens. Emily Wilkins remains optimistic about a swift Senate move following House approval ([43:19]).

5. Corporate Performances: FedEx, Cruise Lines, and American Express

Timestamp: [24:27 - 45:56]

• FedEx:

  • FedEx shares experienced volatility, initially rising 11% post-earnings announcement about spinning off its freight trucking business but later retracing those gains by day's end.
  • Tim Seymour attributed the pullback to macroeconomic pressures impacting pricing and margins, despite enthusiasm over the spin-off strategy ([26:04]).
  • Mike Koh highlighted broader industry scrutiny, noting similar struggles among competitors like Old Dominion, suggesting a challenging environment for shipping firms ([27:00]).

• Cruise Lines:

  • Significant gains were observed in the cruise industry, with companies like Viking Holdings, Norwegian, Royal Caribbean, and Carnival outperforming year-to-date.
  • Steve Liesman attributed this surge to a younger demographic embracing cruises as experiential and family-oriented events, enhancing onboard spending and attracting a broader customer base ([30:24]).
  • Tim Seymour and Mike Koh discussed the resilience and growth prospects of cruise lines, despite general economic uncertainties ([32:00]).

• American Express:

  • American Express (Amex) soared nearly 60% this year, outperforming other financial giants like MasterCard and Visa. The company benefits from its affluent customer base, who tend to pay bills in full, mitigating credit risks.
  • Mike Koh praised Amex's valuation, trading at less than 20 times forward earnings compared to MasterCard's 32+, making it an attractive buy ([39:30]).
  • Steve Liesman emphasized the demographic advantage, noting that Amex is more insulated during market downturns due to its high-income clientele ([40:04]).
  • Tim Seymour expressed cautious optimism, acknowledging Amex's strong performance but questioning the sustainability of its growth rate in the coming year ([40:44]).

6. 2024 Charts of the Year

Timestamp: [33:25 - 38:10]

• Top Contenders:
  • Steve Liesman spotlighted MicroStrategy, highlighting its 3.5-to-1 outperformance relative to Bitcoin, labeling it as the chart of the year. However, he expressed a preference for direct Bitcoin investments via Grayscale Minis over MicroStrategy shares ([34:40 - 35:22]).
  • Tim Seymour presented the RSI Weighted S&P vs. Equal Weighted S&P, illustrating the significant underperformance of the equal-weighted index. He observed that market concentration remains high, with a few dominant stocks driving performance ([34:58 - 36:39]).
  • Carrie Feiderman compared the MAG 7 against the IWM (Russell 2000), noting the MAG 7's continued outperformance despite favorable conditions for small caps. She found the peak divergence surprising, indicating persistent market concentration ([36:23 - 37:24]).
  • Mike Koh focused on the Energy Sector, suggesting potential rebounds despite a decade-long sideways trend. He highlighted the sector's relative undervaluation compared to the S&P 500, presenting it as a viable opportunity for 2025 ([37:33 - 38:10]).

7. Final Trades and Sector Insights

Timestamp: [45:03 - 46:15]

• Health Care Sector:

  • Mike Koh recommended the XLV (Health Care ETF), emphasizing that health care is growing faster than the broader economy while trading cheaper than the S&P 500. He highlighted the sector's resilience and growth potential ([45:49]).

• Spirits and Energy:

  • Tim Seymour mentioned Diageo (Diagnia) as a leading spirits company poised for growth.
  • Carrie Feiderman suggested OIH (Oil Services ETF) as a buy, noting its decline this year has made it even more attractive given the fundamentals ([46:07 - 46:15]).

8. Closing Remarks and Farewells

Timestamp: [24:57 - 46:25]

• Retirement Announcement:

  • Melissa Lee bid farewell to Tyler Matheson, celebrating his 27-year tenure at CNBC. Co-hosts expressed their gratitude and best wishes for his future endeavors ([45:38 - 46:25]).

• Final Advice:

  • Participants reiterated their trading recommendations and sector preferences, emphasizing strategic investments in undervalued sectors and maintaining vigilance in a dynamic market environment.

Key Takeaways:

• Federal Reserve's cautious optimism has led to significant market rebounds, though underlying inflation concerns persist.
• Eli Lilly is currently outperforming Novo Nordisk in the obesity medication space, indicating shifting dynamics in pharmaceutical stocks.
• Government funding negotiations remain a focal point, with successful passage likely averting immediate shutdown threats.
• American Express shines amidst financial stocks, benefiting from its affluent clientele and strong market positioning.
• MicroStrategy and select energy stocks are highlighted as standout performers for 2024, reflecting niche opportunities within the broader market.
• Health care and spirits sectors present compelling investment avenues due to their growth trajectories and undervaluation relative to broader indices.

This episode of "Fast Money" provides comprehensive insights into current market trends, sector performances, and strategic investment opportunities, making it an invaluable resource for investors navigating the complexities of 2024.